1.	Arimidex Observational: Reason for and Effect of Change From Tamoxifen Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D5392NL0002, ARREST, NCT00246961
2.	Arthralgia During Anastrozole Therapy for Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D5392L00013, 2005-00-5441-19 EUDRACT number, NCT00323479
3.	Liver Safety Under Upfront Arimidex vs Tamoxifen Phase: Phase IV Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D5392L00023, NCT00537771
4.	Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-BO16216, CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
5.	Phase III Randomized, Double-Blind Study of Anastrozole vs Tamoxifen as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 06/98) Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: Pharmaceutical / Industry Protocol IDs: ZENECA-1033IL/0030, NCI-V96-1049
6.	Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999) Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: RPCI-DS-97-29, ZENECA-9238IL/0021, NCI-G98-1412
7.	Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy (Arm I and Arm II Closed to Accrual as of 6/15/06) Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI Protocol IDs: NSABP-B-35, SWOG-NSABP-B-35, NCCTG-NSABP-B-35, ACOSOG-NSABP-B-35, NCT00053898
8.	Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, Fluorouracil, and Docetaxel Versus Observation in Women With Relapsed Nonmetastatic Breast Cancer After Initial Conservative Surgery Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: FRE-FNCLCC-PACS-03/003, EU-20237, NCT00053911
9.	Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole in Postmenopausal Women With Receptor-Positive Primary Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: CAN-NCIC-MA27 (COMPANION), NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27
10.	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D5392C00050, SABRE, NCT00082277
11.	Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: CFEM345D2411, NCT00248170
12.	Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy Phase: Phase III Type: Treatment Status: Closed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00002, 9238SW/0001, FACT, NCT00256698
13.	Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 19 to 59 Sponsor: Other Protocol IDs: ABCSG-12, CZOL 446 1B 01, Zol-A-01, NCT00295646
14.	Faslodex Advanced Breast Cancer Local Chinese Study Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00004, NCT00327769
15.	Phase III Randomized Study of Adjuvant Exemestane Versus Anastrozole in Postmenopausal Women With Hormone Receptor-Positive Primary Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 45 and over Sponsor: NCI Protocol IDs: CAN-NCIC-MA27 (NON-COMPANION), NCIC-MA27 (NON-COMPANION), IBCSG-30-04, NCT00438529, MA27
16.	Phase II Study of Anastrozole (Arimidex) in Advanced, Recurrent or Persistent Endometrial Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 to 120 Sponsor: NCI Protocol IDs: GOG-168
17.	Phase II Pilot Study of Sequential High Dose Chemotherapy and CD34+ Selected Stem Cell Support Without Conventional Dose Induction Chemotherapy in Women with Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 to 65 Sponsor: NCI Protocol IDs: NU-HAC98B2, NCI-G00-1689, NCT00004900
18.	Phase II Study of Induction Therapy With Docetaxel and Doxorubicin Followed By Sequential High Dose Chemotherapy and CD34+ Selected Peripheral Blood Stem Cell Support in Women With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 65 Sponsor: NCI Protocol IDs: NU-H97B1, NCI-G00-1682, NCT00004906
19.	Phase II Pilot Study of cDNA Microarray as a Measure of Tumor Response to Neoadjuvant Docetaxel and Capecitabine Followed By Surgery and Adjuvant Doxorubicin and Cyclophosphamide in Patients With Stage II or III Breast Cancer Phase: Phase II Type: Diagnostic, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-00-C-0149, NCT00020241
20.	Phase II Study of Anastrozole and ZD 1839 in Post-Menopausal Women With Estrogen Receptor-Positive, Hormone Refractory, Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CTRC-IDD-0219, CTRC-IDD-1839US, CTRC-IDD-0228, NCT00049062
21.	Phase II Randomized Study of Anastrozole and Gefitinib Versus Fulvestrant and Gefitinib in Postmenopausal Women With Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-4101, E4101, NCT00057941
22.	Phase II Randomized Study of Anastrozole With or Without Gefitinib in Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Other Protocol IDs: EORTC-10021, IDBBC-10021, NCT00066378
23.	Phase II Randomized Study of Adjuvant Radiotherapy Versus Observation in Women With Completely Excised Low-Risk Estrogen Receptor- or Progesterone Receptor-Positive Ductal Carcinoma In Situ of the Breast Receiving Adjuvant Tamoxifen or Anastrozole Phase: Phase II Type: Treatment Status: Closed Age: 40 to 70 Sponsor: Other Protocol IDs: ICR-DCIS-II, EU-20341, NCT00077168
24.	Trial Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839US/0713, NCT00077025
25.	Phase II Randomized Study of Anastrozole With or Without Lonafarnib in Postmenopausal Women With Hormone Receptor-Positive Stage IIIB, IIIC or IV Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0403073-01, SPRI-P03480, NCT00098904